-
British Journal of Anaesthesia Jun 2014
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Infective Agents; Drug Packaging; Female; Humans; Male; Medication Errors; Metronidazole
PubMed: 24829428
DOI: 10.1093/bja/aeu177 -
European Journal of Hospital Pharmacy :... Nov 2020The objectives of this study were to review economic data on the use of closed system drug transfer devices (CSTDs) for preparing and administering hazardous drugs, and... (Review)
Review
OBJECTIVES
The objectives of this study were to review economic data on the use of closed system drug transfer devices (CSTDs) for preparing and administering hazardous drugs, and to evaluate the quality of data reporting as defined by the Consolidated Health Economic Evaluation Reporting Standards (CHEERS).
METHODS
All references from a recent Cochrane review about CSTDs were evaluated for inclusion. A literature review was also conducted. Articles containing economic data about the use of CSTDs were retained for analysis. Two researchers independently graded the articles according to the 24-item CHEERS checklist.
RESULTS
Of the 138 articles identified initially, 12 were retained for analysis. Nine of these studies did not report acquisition costs or did not detail acquisition costs. Six studies reported economic benefits associated with the used of CSTDs, all related to extending the beyond-use date. The mean number of CHEERS criteria fulfilled by the included articles was 9.2 (SD 2.4).
CONCLUSIONS
CSTDs are costly to acquire. However, few studies have examined the economic impact of these devices, and the existing studies are incomplete. As a result, hospitals planning to implement these devices will be unable to make a sound economic evaluation. Robust economic evaluation of CSTDs is needed.
Topics: Cost Savings; Data Interpretation, Statistical; Drug Compounding; Drug Packaging; Drug Storage; Economics, Medical; Hazardous Substances; Humans; Research Design
PubMed: 33097620
DOI: 10.1136/ejhpharm-2018-001775 -
Vaccine Apr 2017The widespread use of multidose vaccine containers in low and middle income countries' immunization programs is assumed to have multiple benefits and efficiencies for... (Review)
Review
The widespread use of multidose vaccine containers in low and middle income countries' immunization programs is assumed to have multiple benefits and efficiencies for health systems, yet the broader impacts on immunization coverage, costs, and safety are not well understood. To document what is known on this topic, how it has been studied, and confirm the gaps in evidence that allow us to assess the complex system interactions, the authors undertook a review of published literature that explored the relationship between doses per container and immunization systems. The relationships examined in this study are organized within a systems framework consisting of operational costs, timely coverage, safety, product costs/wastage, and policy/correct use, with the idea that a change in dose per container affects all of them, and the optimal solution will depend on what is prioritized and used to measure performance. Studies on this topic are limited and largely rely on modeling to assess the relationship between doses per container and other aspects of immunization systems. Very few studies attempt to look at how a change in doses per container affects vaccination coverage rates and other systems components simultaneously. This article summarizes the published knowledge on this topic to date and suggests areas of current and future research to ultimately improve decision making around vaccine doses per container and increase understanding of how this decision relates to other program goals.
Topics: Costs and Cost Analysis; Drug Packaging; Humans; Vaccination; Vaccination Coverage; Vaccines
PubMed: 28162822
DOI: 10.1016/j.vaccine.2016.11.066 -
Anesthesiology Jan 1999
Topics: Anti-Infective Agents, Local; Bacteria; Disinfection; Drug Contamination; Drug Packaging; Humans; Povidone-Iodine
PubMed: 9915351
DOI: 10.1097/00000542-199901000-00056 -
Anaesthesia Apr 1991
Topics: Drug Packaging; Explosions; Floxacillin; Safety
PubMed: 2024760
DOI: 10.1111/j.1365-2044.1991.tb11520.x -
Archives of Disease in Childhood Jan 1989
Topics: Accident Prevention; Child; Drug Packaging; Humans; Ireland; Poisoning
PubMed: 2923472
DOI: 10.1136/adc.64.1.178 -
British Medical Journal Jun 1970
Topics: Child; Drug Packaging; Humans; Poisoning
PubMed: 5428752
DOI: 10.1136/bmj.2.5712.791-d -
Archives of Disease in Childhood Jun 1988
Topics: Accidents, Home; Child, Preschool; Drug Packaging; Humans; Poisoning; United Kingdom
PubMed: 3389888
DOI: 10.1136/adc.63.6.584 -
Yakugaku Zasshi : Journal of the... 2023Selenium is an essential trace element and its deficiency causes myositis, myocardial damage, and other symptoms. Patients receiving long-term intravenous nutrition or...
Selenium is an essential trace element and its deficiency causes myositis, myocardial damage, and other symptoms. Patients receiving long-term intravenous nutrition or tube-feeding in particular are deficient in essential trace elements, including selenium, and require regular supplementation. In Japan, injectable selenium-containing products are listed on the National Health Insurance drug price list, and oral solutions are prepared and used in hospitals. However, these formulations have problems related to preservation and require complicated administration procedures. In this study, we developed a new fast-disintegrating tablet formulation of selenium, using SmartEx (D-mannitol·low substituted hydroxypropylcellulose (L-HPC)·fully hydrolyzed polyvinyl alcohol (PVA) mixture) as a coprocessing additive, that can be administered orally or by feeding tube. The tablet formulation had excellent disintegrable capability, sufficient hardness, and did not cause tube blockage when administered in the simple suspension method. In addition, the tablet formulation showed no changes in properties in an accelerated test without packaging for 42 d, indicating that it could be stored for a long period. Fast-disintegrating tablets prepared with SmartEx are expected to improve the adherence and quality of life of patients who require selenium supplementation.
Topics: Humans; Selenium; Quality of Life; Mannitol; Tablets; Drug Packaging; Administration, Oral; Solubility; Drug Compounding
PubMed: 38044109
DOI: 10.1248/yakushi.23-00101 -
Drug Discoveries & Therapeutics 2022The goal of the current study is to determine stability of compounded 5-fluorouracil (5-FU) in Intravia™ bags and CADD™ cassettes stored up to 15 days under...
The goal of the current study is to determine stability of compounded 5-fluorouracil (5-FU) in Intravia™ bags and CADD™ cassettes stored up to 15 days under refrigeration (2-8°C) and room temperature (25°C with 60% relative humidity), with four different concentrations (20 mg/mL, 30 mg/mL, 40 mg/mL, and 50 mg/mL) and two diluents (0.9% sodium chloride and 5% dextrose). A stability-indicating high-performance liquid chromatography (HPLC) method was developed to analyze the 5-FU concentrations. The stability of compounded 5-FU infusions was investigated using this method. Two samples from each storage condition were assessed for stability on days 0, 4, 7, 10, and 15 as per United States Pharmacopeia (USP) guidelines. The assay of 5-FU was done utilizing a calibrated stability-indicating HPLC method. The stability-indicating HPLC assay showed 5-FU completely degraded within 1 hour in basic conditions. No cloudiness or color change was observed during the stability study. Precipitation was observed in the CADD™ cassettes at day 15 in both storage conditions and at day 10 in a single room-temperature CADD™ cassette for 40 mg/mL in 5% dextrose (D5W). HPLC assay revealed the infusions in CADD™ cassettes retained greater than 90% of the initial concentrations of 5-FU for 15 days stored at room temperature (25°C and 60% relative humidity) and for 10 days at refrigeration (2-8°C). Intravia™ bags retained stability through 15 days for all the compounded 5-FU concentrations and both the storage conditions. 5-FU infusions in both CADD™ cassettes and Intravia™ bags were stable for extendable periods in multiple concentrations compared to recommended guidelines for hospital use.
Topics: Chromatography, High Pressure Liquid; Drug Packaging; Drug Stability; Drug Storage; Fluorouracil; Refrigeration
PubMed: 35264469
DOI: 10.5582/ddt.2022.01011